Life Time Group Holdings Inc. Common Stock vs Organon & Co. Common Stock — how do they compare? Life Time Group Holdings Inc. Common Stock trades at $40.07 (market cap $8.86B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Life Time Group Holdings Inc. Common Stock is far larger — about 2.4× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Life Time Group Holdings Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Life Time Group Holdings Inc. Common Stock for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| LTH | OGN | |
|---|---|---|
Market Cap | $8.86B | $3.62B |
Volume | 3,372,885 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $45.73 | $13.81 |
52-Week Low | $24.59 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $12.91B | $11.04B |
Dividend Yield | — | 0.58% |
Signals from Pluang's Aura AI — not financial advice
Life Time Group Holdings (LTH) trades at $39.66, down 1.76% today, amid bullish technical signals and strong fundamental performance. The stock shows consistent earnings beats, with Q2 2026 EPS of $0.48 exceeding expectations by 28%. Recent expansion news includes new athletic clubs in Florida and Boston, highlighting growth initiatives. Analyst consensus remains strongly bullish with an 86.7% buy rating and $55.17 price target, implying 39% upside.
LTH presents a compelling growth story with expanding facilities and robust profitability margins. Key risks include execution of expansion plans and consumer discretionary spending sensitivity. The valuation at 21.7x P/E appears reasonable given 13% net margins and double-digit ROE. Near-term catalyst is Q3 2026 earnings on October 29, 2026, which could validate the bullish analyst outlook.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Life Time operates fitness and lifestyle centers that offer gyms, classes, sports facilities, and wellness services.
Read more on LTH →Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →